title: Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries.
abstract: Vascular smooth muscle cell (SMC) proliferation is an important component in the development of restenosis. Because endothelin (ET) has been reported to act as an SMC mitogen, we postulated that the orally active ETA receptor antagonist BMS-182874 would suppress the development of the intimal lesion that develops in rat carotid arteries after balloon injury. Using cultured rat aortic SMC, we noted that ET-1-stimulated increases in [3H]thymidine incorporation were blocked by BMS-182874. To determine the effect of the drug on intimal lesion formation, we treated rats with BMS-182874 (100 mg/kg orally, p.o.) or vehicle once daily for 3 weeks, beginning 1 week before balloon injury. Two weeks after injury, drug-treated rats had a 35% decrease in lesion area and a 34% decrease in the lesion/media ratio as compared with the vehicle-treated rats. In situ hybridization (ISH) analysis of balloon-injured rat carotid arteries showed an increase in ETA receptor mRNA. These data support the concept that ETA receptor activation contributes to intimal lesion formation by promotion of SMC proliferation and suggest a potential use for ETA receptor antagonists in the amelioration of hyperproliferative vascular diseases, including restenosis.
authors.affiliation: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.
authors.forename: P
authors.initials: P
authors.lastname: Ferrer
authors.forename: M
authors.initials: M
authors.lastname: Valentine
authors.forename: T
authors.initials: T
authors.lastname: Jenkins-West
authors.forename: H
authors.initials: H
authors.lastname: Weber
authors.forename: N L
authors.initials: NL
authors.lastname: Goller
authors.forename: S K
authors.initials: SK
authors.lastname: Durham
authors.forename: C J
authors.initials: CJ
authors.lastname: Molloy
authors.forename: S
authors.initials: S
authors.lastname: Moreland
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002339:Carotid Arteries / Q000187:drug effects / Q000473:pathology; D002404:Catheterization; D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D003619:Dansyl Compounds / Q000494:pharmacology*; D065128:Endothelin Receptor Antagonists; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000032:analysis / Q000235:genetics
chemical_list: D003619:Dansyl Compounds; D065128:Endothelin Receptor Antagonists; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; C085754:5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide; D004247:DNA